Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects

References

• Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (Concord-2). Lancet. 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/american Society of Clinical Oncology Breast Cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–635.
   PubMed Web of Science ®Google Scholar
• Mock V, Atkinson A, Barsevick A, et al. NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park). 2000;14(11A):151–161.
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Chang-Claude J, Vrieling A, et al. Fatigue and quality of life in breast cancer survivors: temporal courses and long-term pattern. J Cancer Surviv. 2012;6(1):11–19.
   PubMed Web of Science ®Google Scholar
• Goedendorp MM, Andrykowski MA, Donovan KA, et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer. 2012;118(15):3833–3841.
   PubMedGoogle Scholar
• Martín M, Ruiz A, Ruiz Borrego M, et al. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013;31(20):2593–2599.
   PubMed Web of Science ®Google Scholar
• Fisher MI, Davies C, Lacy H, et al. Oncology section EDGE task force on cancer: measures of cancer-related fatigue—a systematic review. Rehab Oncol. 2018;36(2):93–105.
   Web of Science ®Google Scholar
• Fabi A, Bhargava R, Fatigoni S, et al. Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment. Ann Oncol. 2020;31(6):713–723.
   PubMed Web of Science ®Google Scholar
• Vaz-Luis I, Di Meglio A, Havas J, et al. Long-term longitudinal patterns of patient-reported fatigue after breast cancer: a group-based trajectory analysis. J Clin Oncol. 2022;40(19):2148–2162.
   PubMed Web of Science ®Google Scholar
• Puglisi F, Deroma L, Russo S, et al. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol. 2009;69(2):175–182.
   PubMed Web of Science ®Google Scholar
• Russo S, Cinausero M, Gerratana L, et al. Factors affecting patient’s perception of anticancer treatments side-effects: an observational study. Expert Opin Drug Saf. 2014;13(2):139–150.
   PubMed Web of Science ®Google Scholar
• Sobrero A, Puglisi F, Guglielmi A. et alFatigue: a main component of anemia symptomatology. Semin Oncol. 2001;28(2, Suppl 8):15–18.
   PubMed Web of Science ®Google Scholar
• Antonuzzo A, Ripamonti CI, Roila F, et al. Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: a randomized multicenter trial. Front Oncol. 2022;12:925366.
   PubMed Web of Science ®Google Scholar
• Brown JC, Huedo-Medina TB, Pescatello LS, et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2011;20(1):123–133.
   PubMed Web of Science ®Google Scholar
• Tomlinson D, Diorio C, Beyene J, et al. Effect of exercise on cancer-related fatigue: a meta-analysis. Am J Phys Med Rehabil. 2014;93(8):675–686.
   PubMed Web of Science ®Google Scholar
• Mock V, Pickett M, Ropka ME, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 2001;9(3):119–127.
   PubMedGoogle Scholar
• Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022;40(22):2491–2507.
   PubMed Web of Science ®Google Scholar
• Gielissen MFM, Verhagen S, Witjes F, et al. Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol. 2006;24(30):4882–4887.
   PubMed Web of Science ®Google Scholar
• Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232.
   PubMed Web of Science ®Google Scholar
• Buffart LM, van Uffelen JGZ, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012;12(1):559.
   PubMedGoogle Scholar
• Danhauer SC, Addington EL, Cohen L, et al. Yoga for symptom management in oncology: a review of the evidence base and future directions for research. Cancer. 2019;125(12):1979–1989.
   PubMed Web of Science ®Google Scholar
• Barton DL, Liu H, Dakhil SR, et al. Wisconsin ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–1238.
   PubMedGoogle Scholar
• Semiglazov VF, Stepula VV, Dudov A, et al. Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2006;26(2B):1519–1529.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin L, Li H, et al. Effects of acupuncture on cancer-related fatigue: a meta-analysis. supportive care in cancer. J Multinat Assoc Support Care Cancer. 2018;26(2):415–425.
   PubMed Web of Science ®Google Scholar
• Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116(21):5102–5110.
   PubMed Web of Science ®Google Scholar
• Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 2012;43(1):68–77.
   PubMed Web of Science ®Google Scholar
• Richard PO, Fleshner NE, Bhatt JR, et al. Phase II,randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy. BJU Int. 2015;116(5):744–752.
   PubMed Web of Science ®Google Scholar
• Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009;38(5):650–662.
   PubMed Web of Science ®Google Scholar
• Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–3679.
   PubMed Web of Science ®Google Scholar
• Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a university of Rochester cancer center community clinical oncology program research base study. Cancer. 2010;116(14):3513–3520.
   PubMed Web of Science ®Google Scholar
• Morrow GR, Jickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003;21(24):4635–4641.
   PubMed Web of Science ®Google Scholar
• Roscoe A, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005;89(3):243–39.
   PubMed Web of Science ®Google Scholar
• Bruera E, El Osta B, Valero V, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2007;25(23):3475–3481.
   PubMed Web of Science ®Google Scholar
• Dimsdale JE, Ball ED, Carrier E, et al. Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Support Care Cancer. 2011;19(12):2015–2020.
   PubMed Web of Science ®Google Scholar
• Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prevent Cont. 1998;2(2):74–78.
   PubMedGoogle Scholar
• Lund Rasmussen C, Olsen MK, Johnsen AT, et al. Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: a double-blind placebo-controlled crossover trial. Cancer. 2015;121(20):3727–3736.
   PubMed Web of Science ®Google Scholar
• Jim HSL, Hoogland AI, Han HS, et al. A randomized placebo-controlled trial of bupropion for cancer-related fatigue: study design and procedures. Contemp Clin Trials. 2020;91:105976.
   PubMed Web of Science ®Google Scholar
• Palesh OG, Roscoe JA, Mustian KM, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-community Clinical Oncology Program. J Clin Oncol. 2010;28(2):292–298.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Moore PJ, Jones V. The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl). 2001;10(4):245–255.
   PubMed Web of Science ®Google Scholar
• Palesh OG, Collie K, Batiuchok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 2007;75(1):37–44.
   PubMed Web of Science ®Google Scholar
• Leysen L, Lahousse A, Nijs J, et al. Prevalence and risk factors of sleep disturbances in breast cancer survivors: systematic review and meta-analyses. Support Care Cancer. 2019;27(12):4401–4433.
   PubMed Web of Science ®Google Scholar
• Savard J, Ivers H. The initiation of chemotherapy, but not radiation therapy, coincides with increased insomnia. Psychooncology. 2012;21:1–130.
   Web of Science ®Google Scholar
• Palesh O, Peppone L, Innominato F, et al. Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep. 2012;4:151–162.
   PubMedGoogle Scholar
• Sanford SD, Wagner LI, Beaumont JL, et al. Longitudinal prospective assessment of sleep quality: before, during, and after adjuvant chemotherapy for breast cancer. Support Care Cancer. 2013;21(4):959–967.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92(12):994–1000.
   PubMedGoogle Scholar
• Kondratova AA, Kondratov RV. The circadian clock and pathology of the ageing brain. Nat Rev Neurosci. 2012;13(5):325–335.
   PubMed Web of Science ®Google Scholar
• Garaulet M, Madrid J. A. Chronobiological aspects of nutrition, metabolic syndrome and obesity. Adv Drug Deliv Rev. 2010;62(9–10):967–978.
   PubMed Web of Science ®Google Scholar
• Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19(3):895–908.
   PubMed Web of Science ®Google Scholar
• Berger AM, Wielgus K, Hertzog M, et al. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer. 2010;18(1):105–114.
   PubMed Web of Science ®Google Scholar
• Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin cAncer Res Off J Am Assoc Cancer Res. 2005;11(5):1757–1764.
   PubMed Web of Science ®Google Scholar
• Opp MR. Cytokines and sleep. Sleep Med Rev. 2005;9(5):355–364.
   PubMed Web of Science ®Google Scholar
• Liu L, Mills PJ, Rissling M, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun. 2012;26(5):706–713.
   PubMed Web of Science ®Google Scholar
• Panossian LA, Veasey SC. Daytime sleepiness in obesity: mechanisms beyond obstructive sleep apnea—a review. Sleep. 2012;35(5):601–615.
   Web of Science ®Google Scholar
• Lucassen EA, Rother KI, Cizza G. Interacting epidemics? Sleep curtailment, insulin resistance, and obesity. Ann N Y Acad Sci. 2012;1264(1):110–134.
   PubMedGoogle Scholar
• Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. Cancer. 2012;118(8 Suppl):2261–2269.
   PubMedGoogle Scholar
• Gerber LH, Stout N, McGarvey C, et al. Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer. 2011;19(10):1581–1591.
   PubMed Web of Science ®Google Scholar
• Koffel E, Khawaja IS, Germain A. Sleep disturbances in posttraumatic stress disorder: updated review and implications for treatment. Psychiatr Ann. 2016;46(3):173–176.
   PubMed Web of Science ®Google Scholar
• King AC, Oman RF, Brassington GS, et al. Moderate-intensity exercise and self-rated quality of sleep in older adults. a randomized controlled trial. JAMA. 1997;277(1):32–37.
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Yasui U, Vitiello MV, et al. Effects of a year long moderate-intensity exercise and a stretching intervention on sleep quality in postmenopausal women. Sleep. 2003;26(7):830–836.
   PubMed Web of Science ®Google Scholar
• Humpel N, Iverson DC. Sleep quality, fatigue and physical activity following a cancer diagnosis. Eur J Cancer Care (Engl). 2010;19(6):761–768.
   PubMed Web of Science ®Google Scholar
• Young-McCaughan S, Mays MZ, Arzola SM, et al. Research and commentary: change in exercise tolerance, activity and sleep patterns, and quality of life in patients with cancer participating in a structured exercise program. Oncol Nurs Forum. 2003;30(3):441–454.
   PubMedGoogle Scholar
• Mustian KM, Palesh O, Sprod L, et al. Effect of YOCAS yoga on sleep, fatigue, and quality of life: a URCC CCOP randomized, controlled clinical trial among 410 cancer survivors. J Clin Oncol. 2010;28(15_suppl):9013.
   Google Scholar
• Mustian KM, Sprod LK, Janelsins M, et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 2013;31(26):3233–3241.
   PubMed Web of Science ®Google Scholar
• Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. an American Academy of Sleep Medicine Report. Sleep. 2006;29(11):1415–1419.
   PubMed Web of Science ®Google Scholar
• Savard J, Simard S, Ivers H, et al. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol. 2005;23(25):6083–6096.
   PubMed Web of Science ®Google Scholar
• Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol. 2008;26(28):4651–4658.
   PubMed Web of Science ®Google Scholar
• Berger AM, Kuhn BR, Farr LA, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology. 2009;18(6):634–646.
   PubMed Web of Science ®Google Scholar
• Berger AM, Kuhn BR, Farr LA, et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol. 2009;27(35):6033–6040.
   PubMed Web of Science ®Google Scholar
• Barsevick A, Beck SL, Dudley WN, et al. Efficacy of an intervention for fatigue and sleep disturbance during cancer chemotherapy. J Pain Symptom Manage. 2010;40(2):200–216.
   PubMed Web of Science ®Google Scholar
• Chung K, Lee C, Yeung W, et al. Sleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis. Fam Pract. 2018;35(4):365–375.
   PubMed Web of Science ®Google Scholar
• Neikrug AB, Rissling M, Trofimenko V, et al. Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. Behav Sleep Med. 2012;10(3):202–216.
   PubMed Web of Science ®Google Scholar
• Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14(5):563–566.
   PubMed Web of Science ®Google Scholar
• Chen WY, Giobbie-Hurder A, Gantman K, et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145(2):381–388.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Marmiroli P, and Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010;6(12):657–666.
   PubMed Web of Science ®Google Scholar
• Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306–1319.
   PubMed Web of Science ®Google Scholar
• Bao T, Basal C, Seluzicki C, et al. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat. 2016;159(2):327–333.
   PubMed Web of Science ®Google Scholar
• Rivera DR, Ganz PA, Weyrich MS, et al. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018;110(2).
   Google Scholar
• Argyriou AA, Koltzenburg M, Polychronopoulos P, et al. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008;66(3):218–228.
   PubMed Web of Science ®Google Scholar
• Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75(4):659–670.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Cinieri S, Berardi R, et al. EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. BCR. 2020;22(1):83.
   PubMed Web of Science ®Google Scholar
• Tofthagen C, Visovsky CM, Hopgood R. Chemotherapy-induced peripheral neuropathy: an algorithm to guide nursing management. Clin J Oncol Nurs. 2013;17(2):138–144.
   PubMed Web of Science ®Google Scholar
• Crevenna R, Ashbury FD. Physical interventions for patients suffering from chemotherapy-induced polyneuropathy. Support Care Cancer. 2018;26(4):1017–1018.
   PubMed Web of Science ®Google Scholar
• Beijers AJM, Bonhof CS, Mols F, et al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2020;31(1):131–136.
   PubMed Web of Science ®Google Scholar
• Kleckner IR, Kamen C, Cole C, et al. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial. Support Cancer Ther. 2019;27(12):4615–4625.
   PubMed Web of Science ®Google Scholar
• Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer. 2018;26(4):1019–1028.
   PubMed Web of Science ®Google Scholar
• Lu W, Giobbie-Hurder A, Freedman RA, et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist. 2020;25(4):310–318.
   PubMed Web of Science ®Google Scholar
• Kolb NA, Smith G, Singleton JR, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860–866.
   PubMed Web of Science ®Google Scholar
• Tamburin S, Park SB, Schenone A, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022;171:103575.
   PubMed Web of Science ®Google Scholar
• Li Y, Lustberg MB, Hu S. Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy. Cancers (Basel). 2021;13(4):766.
   PubMed Web of Science ®Google Scholar
• Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359.
   PubMed Web of Science ®Google Scholar
• Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase iii trial. Ann Oncol. 2012;23(1):200–205.
   PubMed Web of Science ®Google Scholar
• Kautio A, Haanpää M, Saarto T, et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35(1):31–39.
   PubMed Web of Science ®Google Scholar
• Desforges AD, Hebert CM, Spence AL, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update. Biomed Pharmacother. 2022;147:112671.
   PubMed Web of Science ®Google Scholar
• Szklener K, Szklener S, Michalski A, et al. Dietary supplements in chemotherapy-induced peripheral neuropathy: a new hope? Nutrients. 2022;14(3):625.
   PubMed Web of Science ®Google Scholar
• Zandbergen N, de Rooij BH, Vos MC, et al. Changes in health-related quality of life among gynecologic cancer survivors during the two years after initial treatment: a longitudinal analysis. Acta Oncol. 2019;58(5):790–800.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–3686.
   PubMed Web of Science ®Google Scholar
• Chen VC, Lin T, Yeh D, et al. Predicting chemo-brain in breast cancer survivors using multiple MRI features and machine-learning. Magn Reson Med. 2019;81(5):3304–3313.
   PubMed Web of Science ®Google Scholar
• Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 2004;5(5):273–282.
   PubMed Web of Science ®Google Scholar
• Minisini AM, De Faccio S, Ermacora P, et al. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol. 2008;67(1):71–79.
   PubMed Web of Science ®Google Scholar
• Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. EMBO Mol Med. 2020;12(6):e12075.
   PubMed Web of Science ®Google Scholar
• Breuer B, Anderson R, and Anderson R. The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health. 2000;31(1):71–85.
   PubMed Web of Science ®Google Scholar
• Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64(2):165–176.
   PubMed Web of Science ®Google Scholar
• Phillips K, Regan MM, Ribi K, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–964.
   PubMed Web of Science ®Google Scholar
• van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90(3):210–218.
   PubMed Web of Science ®Google Scholar
• Marín AP, Sánchez AR, Arranz EE, et al. Adjuvant chemotherapy for breast cancer and cognitive impairment. South Med J. 2009;102(9):929–934.
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Neurol. 2003;8(4):201–216.
   Google Scholar
• Chiesa A, Calati R, Serretti A. Does mindfulness training improve cognitive abilities? a systematic review of neuropsychological findings. Clin Psychol Rev. 2011;31(3):449–464.
   PubMed Web of Science ®Google Scholar
• Duval A, Davis CG, Khoo EL, et al. Mindfulness-based stress reduction and cognitive function among breast cancer survivors: a randomized controlled trial. Cancer. 2022;128(13):2520–2528.
   PubMed Web of Science ®Google Scholar
• Hartman SJ, Nelson SH, Myers E, et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: the memory & motion study. Cancer. 2018;124(1):192–202.
   PubMed Web of Science ®Google Scholar
• Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat. 2012;135(3):799–809.
   PubMed Web of Science ®Google Scholar
• Alvarez J, Meyer FL, Granoff DL, et al. The effect of EEG biofeedback on reducing postcancer cognitive impairment. Integr Cancer Ther. 2013;12(6):475–487.
   PubMed Web of Science ®Google Scholar
• Kohli S, Fisher SG, Tra Y, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009;115(12):2605–2616.
   PubMed Web of Science ®Google Scholar
• Shaw EG, Rosdhal R, D’Agostino RB, et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006;24(9):1415–1420.
   PubMed Web of Science ®Google Scholar
• Dinas KD. Impact of breast cancer treatment on fertility. Adv Exp Med Biol. 2020;1252:175–179.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–2370.
   PubMed Web of Science ®Google Scholar
• Goldfarb SB, Turan V, Bedoschi G, et al. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat. 2021;185(1):165–173.
   PubMed Web of Science ®Google Scholar
• Arecco L, Ruelle T, Martelli V, et al. How to protect ovarian function before and during chemotherapy? J Clin Med. 2021;10(18):4192.
   PubMed Web of Science ®Google Scholar
• Moore HCF, Unger JM, Phillips K, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–932.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–13.
   PubMed Web of Science ®Google Scholar
• Bober SL, Fine E, Recklitis CJ. Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors. J Cancer Survivorship. 2020;14(1):26–30.
   PubMed Web of Science ®Google Scholar
• Enemchukwu EA. CO2 laser treatment is effective for symptoms of vaginal atrophy: no. J Urol. 2017;198(6):1228–1229.
   PubMed Web of Science ®Google Scholar
• Arêas F, Valadares Ana LR, Conde DM, et al. The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause. 2019;26(9):1052–1058.
   PubMed Web of Science ®Google Scholar
• Becorpi A, Campisciano G, Zanotta N, et al. Fractional CO2 laser for genitourinary syndrome of menopause in breast cancer survivors: clinical, immunological, and microbiological aspects. Lasers Med Sci. 2018;33(5):1047–1054.
   PubMed Web of Science ®Google Scholar
• Carson JW, Carson KM, Porter LS, et al. Yoga of awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer. 2009;17(10):1301–1309.
   PubMed Web of Science ®Google Scholar
• Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor–positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28(4):634–640.
   PubMed Web of Science ®Google Scholar
• Moegele M, Buchholz S, Seitz S, et al. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet. 2012;285(5):1397–1402.
   PubMed Web of Science ®Google Scholar
• Sanchez-Rovira P, Hirschberg AL, Gil-Gil M, et al. A phase II prospective, randomized, double-blind placebo-controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846–1854.
   PubMed Web of Science ®Google Scholar
• Holmberg L, Anderson H. HABITS (Hormonal Replacement Therapy after Breast Cancer—Is it safe?), A randomised comparison: trial stopped. Lancet. 2004;363(9407):453–455.
   PubMed Web of Science ®Google Scholar
• Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52–59.
   PubMed Web of Science ®Google Scholar
• Sismondi P, Kimmig R, Kubista E, et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients—data from LIBERATE trial. Maturitas. 2011;70(4):365–372.
   PubMed Web of Science ®Google Scholar
• Wurz GT, Soe LH, DeGregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas. 2013;74(3):220–225.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27(17):2831–2837.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12(1):155–158.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356(9247):2059–2063.
   PubMed Web of Science ®Google Scholar
• Boekhout AH, Vincent AD, Dalesio OB, et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011;29(29):3862–3868.
   PubMed Web of Science ®Google Scholar
• Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectrum. 2020;4(1):kz088.
   Web of Science ®Google Scholar
• Rachner TD, Coleman R, Hadji P, et al. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018;6(11):901–910.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–1361.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220.
   PubMed Web of Science ®Google Scholar
• Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J National Compr Cancer Network. 2013;11(suppl 3):S-1-S–50.
   Google Scholar
• Zamorano JL, Lancellotti P, Muñoz DR, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
   PubMed Web of Science ®Google Scholar
• Moliterni A, Bonadonna G, Valagussa P, et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol. 1991;9(7):1124–1130.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA. 1995;273(7):542–547.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zambetti M, Bumma C, et al. Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group. Ann Oncol. 2002;13(7):1049–1058.
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Dunn JA, et al. for the NEAT Investigators and the SCTBG. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer. 2012;107(8):1257–1267.
   PubMed Web of Science ®Google Scholar
• Von Hoff D. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710.
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Gianni L, Santoro A, et al. Drugs ten years later: epirubicin. Ann Oncol. 1993;4(5):359–369.
   PubMed Web of Science ®Google Scholar
• Wojtukiewicz MZ, Omyla J, Kozlowski L, et al. Cardiotoxicity of anthracycline. Postepy Hig Med Dosw (Online). 2000;54(4):467–485.
   Google Scholar
• Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Euro Heart J Cardiovascular Imaging. 2014;15(10):1063–1093.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2010;55(3):213–220.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy–induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474–2481.
   PubMed Web of Science ®Google Scholar
• Raccomandazioni pratiche. CARDIO-ONCOLOGIA 2019. N.d. n.d.
   Google Scholar
• van Dalen EC, van der Pal HJH, Kremer LCM. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Edited by Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Cochrane Database Syst Rev. 2016.
   Web of Science ®Google Scholar
• Rafiyath SM, Rasul M, Lee B, et al. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1(1):10.
   PubMedGoogle Scholar
• Yamaguchi N, Fujii T, Aoi S, et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer. 2015;51(16):2314–2320.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl(CAELYXTM/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449.
   PubMed Web of Science ®Google Scholar
• Lyon AR, López-Fernández T, Couch LS, et al. ESC scientific document group, 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Euro Heart J Cardiovascular Imaging. 2022;23(10):e333–e465.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. edited by Cochrane gynaecological, neuro-oncology and orphan cancer group. Cochrane Database Syst Rev. 2011;2016(9).
   Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337.
   PubMed Web of Science ®Google Scholar
• Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children’s Oncology Group randomized trial Pediatric Oncology Group 9404. J Clin Oncol. 2016;34(8):854–862.
   PubMed Web of Science ®Google Scholar
• Reichardt P, Tabone M, Mora J, et al. Risk–benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663–2676.
   PubMed Web of Science ®Google Scholar
• Caspani F, Tralongo AC, Campiotti L, et al. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(2):477–486.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Hirji S, Qamar A, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. J Am Coll Cardiol CardioOnc. 2019;1(1):54–65.
   Google Scholar
• Li X, Li Y, Zhang T, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 2020;151:104577.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition. Circulation. 2006;114(23):2474–2481.
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–1680.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Jirji SA, Qamar A, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC: CardioOncology. 2019;1(1):54–65.
   PubMedGoogle Scholar
• Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306–2310.
   PubMed Web of Science ®Google Scholar
• Shah P, Garris R, Abboud R, et al. Meta-analysis comparing usefulness of beta blockers to preserve left ventricular function during anthracycline therapy. Am J Cardiol. 2019;124(5):789–794.
   PubMed Web of Science ®Google Scholar
• Ma Y, Bai F, Qin F, et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):18.
   PubMedGoogle Scholar
• Huang S, Zhao Q, Yang ZG, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev. 2019;24(3):325–333.
   PubMed Web of Science ®Google Scholar
• Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39(8):974–984.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991;9(9):1704–1712.
   PubMed Web of Science ®Google Scholar
• Martel S, Maurer C, Lambertini M, et al. Breast cancer treatment-induced cardiotoxicity. Expert Opin Drug Saf. 2017;16(9):1021–1038.
   PubMed Web of Science ®Google Scholar
• Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1(4):e000073.
   PubMed Web of Science ®Google Scholar
• Moja L., Brambilla C., Compagnoni A., et al. Trastuzumab Containing Regimens for Early Breast Cancer. In Cochrane Database of Systematic Reviews, edited by The Cochrane Collaboration. 2006
   Google Scholar
• Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Advani PP, Ballman KV, Dockter TJ, et al. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;34(6):581–587.
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547–558.
   PubMed Web of Science ®Google Scholar
• Jawa Z, Perez RM, Garlie L, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore). 2016;95(44):e5195.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382(9897):1021–1028.
   PubMed Web of Science ®Google Scholar
• Barish R, Gates E, Barac A. Trastuzumab-Induced Cardiomyopathy. Cardiol Clin. 2019 18;37(4):407–418.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–3916.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang C, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with Trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–640.
   PubMed Web of Science ®Google Scholar
• Wood ME, Vogel V, Ng A, et al. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734–3745.
   PubMed Web of Science ®Google Scholar
• Smith RE, Bryant J, DeCillis A, et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol. 2003;21(7):1195–1204.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015;33(4):340–348.
   PubMed Web of Science ®Google Scholar
• Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389–1398.
   PubMed Web of Science ®Google Scholar
• Azarova AM, Lyu YL, Lin C, et al. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007;104(26):11014–11019.
   PubMed Web of Science ®Google Scholar
• Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst. 2000;92(14):1165–1171.
   PubMedGoogle Scholar
• Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340(5):351–357.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Visser O, Louwman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol. 2008;26(8):1239–1246.
   PubMed Web of Science ®Google Scholar
• Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and risk of subsequent malignant neoplasms in the childhood cancer survivor study cohort. J Clin Oncol. 2019;37(34):3310–3319.
   PubMedGoogle Scholar